Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Objectives To characterize the risk factors, rate of occurrence, onset, nature and impact of mild to moderate muscular symptoms with high-dosage HMG-CoA reductase inhibitor (statin) therapy in general practice.Methods The Prédiction du Risque Musculaire en Observationnel (Prediction of Muscular Risk in Observational conditions, PRIMO) survey was an observational study of muscular symptoms in an unselected population of 7924 hyperlipidemic patients receiving high-dosage statin therapy in a usual care, outpatient setting in France. Information on patient demographics, treatment history and muscular symptoms was obtained by questionnaires.Results Multivariate analysis revealed the strongest predictors for muscular symptoms to be a personal history of muscle pain during lipid-lowering therapy (odds ratio, OR, 10.12, 95% CI 8.23-12.45; P < 0.0001), unexplained cramps (OR 4.14; 95% CI 3.46-4.95; P < 0.0001) and a history of creatine kinase (CK) elevation (OR 2.04; 95% CI 1.55-2.68; P < 0.0001). Overall, muscular symptoms were reported by 832 patients (10.5%), with a median time of onset of 1 month following initiation of statin therapy. Muscular pain prevented even moderate exertion during everyday activities in 315 patients (38%), while 31 (4%) were confined to bed or unable to work. Fluvastatin XL was associated with the lowest rate of muscular symptoms (5.1%) among individual statins.Conclusion PRIMO demonstrated that mild to moderate muscular symptoms with high-dosage statin therapy may be more common and exert a greater impact on everyday lives than previously thought. Knowledge of the risk factors for muscular symptoms will allow identification and improved management of high-risk patients. The risk of muscular symptoms with fluvastatin XL treatment may be lower than with high dosages of other statins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consequently, the development of SAMS interferes with the patient’s quality of life and can lead to reduction of statin dose or discontinuation of statin therapy.(10,12)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [10]
In the citing paper
“SAMS are prevalent in 5–20 % of statin taking patients and cover a range of mild to moderate muscle symptoms, including muscle pain, muscle cramps, muscle weakness, and muscle stiffness.(10)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [10]
In the citing paper
“SAMS are prevalent in 5–20 % of statin taking patients and cover a range of mild to moderate muscle symptoms, including muscle pain, muscle cramps, muscle weakness, and muscle stiffness.(10)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [10]
In the citing paper
“Previous investigations show that the risk of developing myopathy is dose-dependent, and statin-type is a predictor for SAMS, with higher numbers of SAMS in patients administered to lipophilic statins.(10,44)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [10]
In the citing paper
“Statins are not effective in a few specific groups, notably those with heart failure (HF) or patients receiving haemodialysis [214,218-222].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [220]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720 · cited 1×
“Thus, atorvastatin, 40–80 mg/day and simvastatin, 40–80 mg/day lower LDL-C levels to a greater extent compared with either fluvastatin, 80 mg/day or pravastatin, 40 mg/day [28].”
BackgroundThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333 · cited 1×
“Indeed, the increased risk of muscular side effects with high-dosage statin therapy was recently illustrated by the Aggrastat to Zocor (A to Z) trial [20].”
BackgroundACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A. (2002) · JAMA · doi:10.1001/jama.288.4.462 · Cited by 1,077
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626 · cited 2×
“Moreover, fluvastatin treatment has also been associated with the lowest number of published cases of rhabdomyolysis [30], and the lowest published incidence of fatal rhabdomyolysis [12], among statins in clinical practice.”
BackgroundPasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02030-2 · Cited by 497
Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453 · cited 3×
“Indeed, most of the clinically important drug-drug interactions that occur with statins are attributable to the concurrent use of statins that are recognized by cytochrome P450 (CYP) isoform 3A4 (such as atorvastatin and simvastatin) and other agents that are potent inhibitors of this enzyme [19].”
BackgroundInfluentialSauret, J. M., Marinides, G. N., & Wang, G. K. (2002) · PubMed · Cited by 222
Dart, A., Jerums, G., Nicholson, G., d'Emden, M., Hamilton-Craig, I., Tallis, G., Best, J., West, M., Sullivan, D., Braes, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00280-4 · Cited by 187
(1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90858-a · Cited by 182
Lovastatin increases exercise-induced skeletal muscle injury
Thompson, P. D., Zmuda, J. M., Domalik, L. J., Zimet, R. J., Staggers, J., & Guyton, J. R. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90218-3 · Cited by 177 · cited 1×
“Symptomatic patients were generally more active than the population as a whole; this may be because active patients are more likely to sustain the type of low-level injury that is exacerbated by statins [ 26 ].”
BackgroundFischer, V., Johanson, L., Heitz, F., Tullman, R. H., Graham, E., Baldeck, J. P., & Robinson, W. T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14919-7 · Cited by 149
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Bertolini, S., Bon, G., Campbell, L., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., Sirtori, C., Egros, F., Fayyad, R., et al. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06052-2 · Cited by 140
Muscular Side Effects of Statins
Sinzinger, H. F., Wolfram, R. M., & Peskar, B. A. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200208000-00001 · Cited by 127 · cited 1×
“Moreover, mild muscular symptoms are often overlooked by doctors, and their frequency is therefore probably underestimated [18].”
BackgroundA Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs
Franc, S., Dejager, S., Bruckert, É., Chauvenet, M., Giral, P., & Turpin, G. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/b:card.0000015861.26111.ab · Cited by 122 · cited 4×
“This result is, however, consistent with a preliminary study [22], and we believe it provides a more accurate reflection of statin tolerability in general practice (at least for high-dosage statin therapy) than clinical trial data.”
MethodResultSelf-citationBradford, R. H., Shear, C. L., Chremos, A. N., Dujovne, C. A., Franklin, F. A., Grillo, R. B., Higgins, J., Langendörfer, A., Nash, D. T., Pool, J. L., et al. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90307-7 · Cited by 109
Clinical Features, Pathogenesis and Management of Drug-Induced Rhabdomyolysis
Köppel, C. (1989) · Drug Safety · doi:10.1007/bf03259907 · Cited by 85 · cited 1×
“Finally, it is important to draw attention to the possibility that the risk factors for mild to moderate muscular symptoms and those for severe rhabdomyolysis might be quite distinct, a possibility which is all the more likely since it is well documented that rhabdomyolysis may occur without any prior symptoms at all…”
BackgroundCan Statins Cause Chronic Low-Grade Myopathy?
Grundy, S. M. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00015 · Cited by 64 · cited 1×
“Nevertheless, the risk factors, presentation and impact of mild to moderate muscular side effects of statin therapy are poorly understood [17].”
BackgroundUpdated clinical safety experience with fluvastatin
Jokubaitis, L. A. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90628-9 · Cited by 51
Bruckert, É., Simonetta, C., & Giral, P. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00019-0 · Cited by 51 · cited 2×
“The potential clinical impact of mild muscular side effects of statin treatment should not be underestimated, as hypercholesterolemic patients who experience adverse events are more likely to discontinue statin therapy [14].”
BackgroundCsako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40 · cited 2×
“It is well known that the risk of muscular side effects with statin therapy is increased by drug interactions with agents that interfere with statin elimination [30].”
BackgroundSteinhagen‐Thiessen, E. (2008) · Cardiology · doi:10.1159/000176682 · Cited by 38
Lambrecht, L., & Malini, P. L. (1993) · PubMed · Cited by 37
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Bakker-Arkema, R. G., Nawrocki, J. W., & Black, D. M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00294-4 · Cited by 36
Frequency of creatine kinase elevation during treatment with fluvastatin
Benghozi, R., Bortolini, M., Jia, Y., Isaacsohn, J. L., Troendle, A. J., & Gonasun, L. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02209-3 · Cited by 36 · cited 1×
“Fluvastatin demonstrated an incidence of CK elevations similar to placebo in a pooled analysis of 8951 patients receiving fluvastatin or fluvastatin XL treatment in clinical studies [29].”
Result
Research works printed but not linked: 2
- Adverse Drug Reactions Advisory Committee (ADRAC). Risk factors for myopathy and rhabdomyolysis with the statins. Aust Adv Drug Reactions Bull 2004;23(1):1–2.
- Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35(9):1096–1107. · doi:10.1345/aph.10228 · Paper page
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Patients taking statin therapy frequently report muscle symptoms [so-called ‘statin-associated muscle symptoms’ (SAMS)], and in nonrandomized, observational studies, statins are associated with muscular pain and tenderness (myalgia) without CK elevation or major functional loss, with the reported frequency of SAMS in…”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Metadata
- Authors
- Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Novartis (France) (FR)
- Université Bordeaux Segalen (FR)
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2005-12
- Volume
- 19
- Issue
- 6
- Pages
- 403-414
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2010033213
- Cited by
- 1,226
- References
- 37
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 49 · 2023: 52 · 2022: 51 · 2021: 53 · 2020: 80 · 2019: 80 · 2018: 87 · 2017: 84 · 2016: 115 · 2015: 99 · 2014: 110 · 2013: 77 · 2012: 66
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin-induced myopathy, statins, hyperlipidemia, risk factors, myalgia, creatine kinase elevation, statin adverse effects
- MeSH terms
- Aged, Alcohol Drinking, Dose-Response Relationship, Drug, Female, France, Humans, Hyperlipidemias, Male, Middle Aged, Musculoskeletal Diseases, Outpatients, Pain, Predictive Value of Tests, Surveys and Questionnaires, Risk Factors, Smoking, Multivariate Analysis, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.